Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new human antitumor immunoreagent specific for ErbB2.

Claudia De Lorenzo1, Donald B Palmer, Renata Piccoli

  • 1Department of Biological Chemistry, University of Naples Federico II, via Mezzocannone 16, 80134 Naples, Italy.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 13, 2002
PubMed
Summary

Researchers isolated a novel human mini-antibody (scFv) targeting ErbB2-positive cancers. This antibody inhibits ErbB2, internalizes into cancer cells, and shows potent antitumor effects, especially in high-ErbB2 expressing tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Journal of cardiovascular pharmacology·2026
Same author

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort.

EBioMedicine·2025
Same author

Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy.

Frontiers in immunology·2025
Same author

A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.

International journal of molecular sciences·2025
Same author

International Consortium to Classify Ageing-related Pathologies (ICCARP) senescence definitions: achieving international consensus.

GeroScience·2025
Same author

Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Cell death discovery·2025

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • ErbB2 (Human Epidermal growth factor Receptor 2) is a tyrosine kinase receptor.
  • ErbB2 is overexpressed in various significant carcinomas, including breast, ovary, and lung cancers.
  • ErbB2 expression is limited in normal tissues, making it a specific cancer target.

Purpose of the Study:

  • To isolate a novel human single-chain variable fragment (scFv) mini-antibody.
  • To develop an scFv that specifically targets ErbB2-positive cancer cells.

Main Methods:

  • Utilized a large phagemid library (Griffin.1) for scFv isolation.
  • Employed a double subtractive selection strategy with ErbB2-positive and negative cell lines.

Main Results:

Related Experiment Videos

  • Isolated the first human anti-ErbB2 mini-antibody with antitumor activity.
  • The scFv specifically binds ErbB2, inhibits its autophosphorylation, and is internalized by target cells.
  • Demonstrated potent antiproliferative action on ErbB2-positive cells, with increased cytotoxicity and apoptosis in hyper-expressing cells like SKBR3.

Conclusions:

  • The isolated scFv is a promising immunoreagent for cancer diagnostics and therapeutics.
  • It can be utilized as a diffused molecule in solid tumors.
  • This scFv is valuable for developing fully human anticancer drugs.